ONO-9054

DRUG3 trials

Sponsors

Ono Pharma USA Inc, Ono Pharmaceutical Co. Ltd

Conditions

Healthy Adult SubjectsMild Open Angle-glaucoma (OAG)Ocular HypertensionOcular Hypertension (OHT)Open Angle-glaucoma

Phase 1

Single Dose Escalation Study of ONO-9054 in Healthy Volunteers

CompletedNCT01508988

Ono Pharma USA IncHealthy Adult Subjects

Start: 2012-01-31Updated: 2012-06-14

Single and Multiple Dose Escalation and Two-sequence Crossover Study of ONO-9054 in Patients With Ocular Hypertension or Mild Open-angle Glaucoma

CompletedNCT01670266

Ono Pharma USA IncMild Open Angle-glaucoma (OAG), Ocular Hypertension (OHT)

Start: 2012-08-31Updated: 2013-06-03

Phase 2

A 28 Day Study of ONO-9054 Ophthalmic Solution in Subjects With Ocular Hypertension (OHT) or Open-angle Glaucoma (OAG)

CompletedNCT02083289

Ono Pharmaceutical Co. LtdOcular Hypertension, Open Angle-glaucoma

Start: 2014-05-31Updated: 2016-02-25

Related Papers

Ocular hypotensive effect of the novel EP3/FP agonist ONO-9054 versus Xalatan: results of a 28-day, double-masked, randomised study

British Journal of Ophthalmology2016-09-2030 citations

A Novel Dual Agonist of EP3 and FP Receptors for OAG and OHT: Safety, Pharmacokinetics, and Pharmacodynamics of ONO-9054 in Healthy Volunteers

Investigative Ophthalmology & Visual Science2015-12-1722 citations

EP3/FP dual receptor agonist ONO-9054 administered morning or evening to patients with open-angle glaucoma or ocular hypertension: results of a randomised crossover study

British Journal of Ophthalmology2015-10-0916 citations